• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience.管理高危神经母细胞瘤患儿的局部区域性失败:单机构经验。
Pediatr Blood Cancer. 2018 Dec;65(12):e27408. doi: 10.1002/pbc.27408. Epub 2018 Sep 30.
2
Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience.根治性放疗治疗单纯手术一线治疗后复发的下咽及喉鳞状细胞癌:10 年单中心经验。
Radiat Oncol. 2019 Feb 19;14(1):34. doi: 10.1186/s13014-019-1238-8.
3
Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery.口腔鳞状细胞癌术后辅助放疗和挽救性放疗的长期预后
Laryngoscope. 2018 Nov;128(11):2539-2545. doi: 10.1002/lary.27191. Epub 2018 Apr 10.
4
Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.拓扑替康联合环磷酰胺治疗儿童神经母细胞瘤首次复发。
Pediatr Blood Cancer. 2013 Oct;60(10):1636-41. doi: 10.1002/pbc.24587. Epub 2013 May 3.
5
Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials.复发、高危神经母细胞瘤患者的治疗和结局:德国试验的结果。
Pediatr Blood Cancer. 2011 Apr;56(4):578-83. doi: 10.1002/pbc.22693. Epub 2010 Dec 9.
6
Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy.多模态治疗对头颈部皮肤鳞状细胞癌患者的疾病复发与生存结局的相关性。
JAMA Dermatol. 2019 Apr 1;155(4):442-447. doi: 10.1001/jamadermatol.2018.5453.
7
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.神经母细胞瘤患儿进展或复发后的结局。意大利神经母细胞瘤登记处的回顾性研究。
Eur J Cancer. 2009 Nov;45(16):2835-42. doi: 10.1016/j.ejca.2009.06.010. Epub 2009 Jul 16.
8
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.大剂量化疗及自体造血干细胞救援用于高危神经母细胞瘤患儿
Cochrane Database Syst Rev. 2013 Aug 22(8):CD006301. doi: 10.1002/14651858.CD006301.pub3.
9
Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy.对于既往未接受辅助治疗的孤立性阴道复发子宫内膜癌,采用挽救性高剂量率近距离放疗和外照射放疗。
Brachytherapy. 2017 Nov-Dec;16(6):1152-1158. doi: 10.1016/j.brachy.2017.07.002. Epub 2017 Aug 10.
10
Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group.鼻咽癌首次局部失败患者的生存结局:香港鼻咽癌研究组的一项研究
Head Neck. 2005 May;27(5):397-405. doi: 10.1002/hed.20161.

引用本文的文献

1
Role and practical guidelines for the use of radiotherapy in neuroblastoma - a narrative review of literature and clinical trial protocols.神经母细胞瘤放射治疗的作用及实用指南——文献与临床试验方案的叙述性综述
Rep Pract Oncol Radiother. 2025 Aug 7;30(3):424-438. doi: 10.5603/rpor.106279. eCollection 2025.
2
Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma.在高危神经母细胞瘤的同基因小鼠模型中,将免疫疗法与高剂量放射疗法(HDRT)相结合可显著抑制肿瘤生长。
Heliyon. 2023 Jun 19;9(6):e17399. doi: 10.1016/j.heliyon.2023.e17399. eCollection 2023 Jun.
3
Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.质子束治疗复发性高危神经母细胞瘤的疗效和可行性——来自前瞻性 KiProReg 注册研究的经验。
Curr Oncol. 2022 Oct 30;29(11):8222-8234. doi: 10.3390/curroncol29110649.

本文引用的文献

1
Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.伊立替康-替莫唑胺联合替西罗莫司或地努图希单抗治疗难治性或复发性神经母细胞瘤患儿(COG ANBL1221):一项开放标签、随机、2期试验。
Lancet Oncol. 2017 Jul;18(7):946-957. doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23.
2
Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.贝伐单抗、伊立替康和替莫唑胺联合治疗难治性或复发性神经母细胞瘤:一项II期研究结果
Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26448. Epub 2017 Jan 23.
3
Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis.小儿神经母细胞瘤立体定向体部放射治疗(SBRT)短间隔再治疗导致严重肌炎
Pediatr Blood Cancer. 2016 Apr;63(4):731-3. doi: 10.1002/pbc.25863. Epub 2016 Jan 25.
4
Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).(131)I-间位碘代苄胍((131)I-MIBG)治疗后复发与难治性神经母细胞瘤的不同结局。
Eur J Cancer. 2015 Nov;51(16):2465-72. doi: 10.1016/j.ejca.2015.07.023. Epub 2015 Aug 5.
5
Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.用于高危神经母细胞瘤的快速COJEC与标准诱导疗法对比
Cochrane Database Syst Rev. 2015 May 19;2015(5):CD010774. doi: 10.1002/14651858.CD010774.pub2.
6
Neuroblastoma: paradigm for precision medicine.神经母细胞瘤:精准医学的范例
Pediatr Clin North Am. 2015 Feb;62(1):225-56. doi: 10.1016/j.pcl.2014.09.015.
7
Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project.神经母细胞瘤复发后生存预测的临床和生物学特征:国际神经母细胞瘤风险组项目的报告。
J Clin Oncol. 2011 Aug 20;29(24):3286-92. doi: 10.1200/JCO.2010.34.3392. Epub 2011 Jul 18.
8
Local control, survival, and operative morbidity and mortality after re-resection, and intraoperative radiation therapy for recurrent or persistent primary high-risk neuroblastoma.再次切除后局部控制、生存和手术并发症发生率和死亡率,以及复发性或持续性原发性高危神经母细胞瘤的术中放疗。
J Pediatr Surg. 2011 Jan;46(1):97-102. doi: 10.1016/j.jpedsurg.2010.09.068.
9
Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.拓扑替康联合环磷酰胺与拓扑替康单药治疗复发或难治性神经母细胞瘤患儿的 II 期随机对照研究:一项儿童肿瘤学组研究。
J Clin Oncol. 2010 Aug 20;28(24):3808-15. doi: 10.1200/JCO.2009.27.5016. Epub 2010 Jul 26.
10
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.1岁以上4期神经母细胞瘤患者的大剂量快速诱导化疗与标准诱导化疗:一项随机试验
Lancet Oncol. 2008 Mar;9(3):247-56. doi: 10.1016/S1470-2045(08)70069-X.

管理高危神经母细胞瘤患儿的局部区域性失败:单机构经验。

Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience.

机构信息

College of Medicine and Department of Radiation Oncology, West Cancer Center, University of Tennessee Health Science Center, Memphis, Tennessee.

Department of Radiation Oncology, West Cancer Center, University of Tennessee Health Science Center, Memphis, Tennessee.

出版信息

Pediatr Blood Cancer. 2018 Dec;65(12):e27408. doi: 10.1002/pbc.27408. Epub 2018 Sep 30.

DOI:10.1002/pbc.27408
PMID:30270551
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6192847/
Abstract

BACKGROUND

Intensification of systemic therapy for high-risk neuroblastoma (HRNB) has resulted in improved local control and overall survival (OS) leaving potential for de-escalation of primary site radiotherapy. The utility of primary site de-escalation should be evaluated in the context of potential for successful local-regional salvage. We evaluated salvage strategies and outcomes in patients with HRNB with local-regional recurrence as a component of first failure.

METHODS

Twenty of 89 patients with HRNB experienced local-regional recurrence as a component of first relapse after chemotherapy, radiotherapy, surgery, and stem cell transplant from 1997 to 2013. We reviewed salvage therapy strategies and disease control, and report on the impact of local therapy as salvage for local-regional relapse.

RESULTS

Six of 20 patients with local-regional failure (LRF) were alive after a median follow-up of 13 years (range, 0.9-25.2 years). Median OS was 4.6 years (95% CI, 0.6 to not reached) versus 0.6 years (95% CI, 0.05-2.6) after LRF with and without distant failure, respectively (P = 0.03). OS in patients receiving salvage radiotherapy was comparable to those receiving initial adjuvant but no salvage radiotherapy. Time to first failure and death was significantly impacted by the intensity of frontline systemic therapy (P = 0.03). Salvage radiotherapy reduced the hazard for subsequent LRF (hazard ratio 0.3, 95% CI 0.1-0.9, P = 0.04) but not OS (P = 0.07).

CONCLUSIONS

Our study highlights the potential of local control strategies at first failure in patients with LRF when primary site radiotherapy was initially omitted, and delineates potential selection factors which may further improve the therapeutic ratio.

摘要

背景

高危神经母细胞瘤(HRNB)的全身治疗强化已导致局部控制和总体生存(OS)得到改善,从而有可能降低原发部位放疗的剂量。在可能成功进行局部区域挽救的情况下,应评估原发部位降级的效用。我们评估了 HRNB 患者中局部区域复发作为首次失败的一部分的挽救策略和结局。

方法

1997 年至 2013 年,89 例 HRNB 患者中有 20 例在化疗、放疗、手术和干细胞移植后出现局部区域复发作为首次复发的一部分。我们回顾了挽救治疗策略和疾病控制情况,并报告了局部治疗作为局部区域复发挽救的作用。

结果

20 例局部区域失败(LRF)患者中有 6 例在中位随访 13 年后(范围,0.9-25.2 年)存活。LRF 伴或不伴远处失败患者的中位 OS 分别为 4.6 年(95%CI,0.6-未达到)和 0.6 年(95%CI,0.05-2.6)(P=0.03)。接受挽救性放疗的患者的 OS 与接受初始辅助治疗但无挽救性放疗的患者相当。一线全身治疗强度显著影响首次失败和死亡的时间(P=0.03)。挽救性放疗降低了随后发生 LRF 的风险(风险比 0.3,95%CI 0.1-0.9,P=0.04),但对 OS 无影响(P=0.07)。

结论

我们的研究强调了在最初省略原发部位放疗时,LRF 患者在首次失败时局部控制策略的潜力,并描述了可能进一步提高治疗比的潜在选择因素。